Waystar Holding Corp., an American technology company focused on healthcare software solutions, completed its acquisition of Iodine Software, LLC for a total consideration of $920 million, the companies announced.

AcquirerWaystar Holding Corp. (US)
TargetIodine Software, LLC (US)
Deal value$920m
TypeAcquisition
Closing dateFebruary 24, 2025
AdvisorsJ.P. Morgan, Goldman Sachs & Co., Barclays, Barclays Capital Inc.

Deal mechanics

The transaction included a cash consideration of $625 million paid by Waystar Holding Corp. Additionally, 16.8 million common equity shares of Waystar Holding Corp. will be issued for the corresponding amount of Iodine Software's common stock.

Strategic rationale

The acquisition is aimed at raising capital through a public offering to support further growth initiatives and extend its leadership in healthcare AI software solutions. The combination of Waystar’s extensive market presence with Iodine Software’s advanced technology will enhance their competitive edge within the rapidly evolving tech sector.

Financial context

EQT, a private equity firm, recently completed a public offering for common stock of Waystar Holding Corp., enabling the company to secure additional funding necessary for the acquisition. This strategic move reflects Waystar’s commitment to expanding its portfolio and reinforcing its position as a dominant player in healthcare technology.

Advisors

J.P. Morgan, Goldman Sachs & Co., and Barclays served as financial advisors to Waystar Holding Corp. Simpson Thacher & Bartlett LLP provided legal counsel for the buy-side while Weil, Gotshal & Manges LLP and Queen Saenz + Schultz PLLC represented Iodine Software.

Outlook

The successful completion of this deal marks a significant milestone in Waystar’s growth strategy. With increased financial resources and technological prowess, the company is poised to deliver innovative solutions that cater to evolving healthcare industry needs. Further announcements regarding integration plans are expected in the coming months.